Genomics Core

基因组学核心

• 批准号: 10327770
• 负责人: Jill A. Macoska
• 金额: $ 13.49万
• 依托单位: UNIVERSITY OF MASSACHUSETTS BOSTON
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-28 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10327770
• 关键词: Address; African; African American; Androgen Receptor; BRCA2 gene; Bioinformatics; Biomedical Research; Biostatistical Methods; Boston; CHD1 gene; Cancer Biology; Cancer Center; Code; DNA Sequence; Dana-Farber Cancer Institute; Data; Data Analyses; Education and Outreach; Educational workshop; Fees; Frequencies; Genomic approach; Genomics; Goals; Infrastructure; Institution; Instruction; Lead; Learning; Malignant neoplasm of prostate; Massachusetts; Minority-Serving Institution; Modeling; Outcome; Population; Prostatic Neoplasms; RNA; Receptor Signaling; Research; Research Design; Research Personnel; Research Training; Resources; Reverse Transcriptase Polymerase Chain Reaction; Risk; SNP genotyping; Structure; Students; Technology; Training; Underrepresented Populations; Underrepresented Students; Universities; Untranslated RNA; anticancer research; base; cancer health disparity; cancer initiation; cancer risk; cost; design; education research; experience; genomic data; health disparity populations; innovation; instrumentation; men; nano-string; next generation sequencing; novel; personalized cancer therapy; programs; single cell sequencing; therapy resistant; tool; tumor progression

SUMMARY A critical gap often exists at institutions serving underserved health disparity populations and underrepresented students (ISUPS) between access to Genomics technologies and the high costs associated with the required instrumentation, technical proficiency, and analytical expertise. The Genomics Core (GC) addresses this gap by providing expert and affordable access to high-throughput genomics technologies on a reduced fee basis for all Partnership investigators. The GC benefits the entire Partnership by providing innovative approaches to explore early project ideas, and by working with Partnership investigators and their trainees to facilitate the use of genomics technologies to build sustainable cancer biology and cancer disparities research. To accomplish these goals, the GC (through the auspices of the Center for Personalized Cancer Therapy, CPCT) provides front-line genomics-related technologies, as well as bioinformatics support for data analysis, to Partnership investigators through an affordable reimbursement model. The GC proposes to accomplish these goals through the pursuit of four specific aims designed to build capacity for biomedical and cancer research and training at UMass Boston by bridging a gap in the availability of cutting-edge genomics-based tools; support Partnership investigators who wish to pursue early project ideas, especially those that require innovative and/or technically challenging genomics approaches; bridge a training gap between students and high-level genomics-based technologies, and provide bioinformatics analysis of data generated in the core. In this application, the GC specifically supports FP2: Targeting androgen receptor signaling in prostate cancer in men with African Ancestry – Steven Balk (DF/HCC - BIDMC) and Changmeng Cai (UMass Boston) and PP2: High frequency of CHD1 loss in BRCA2-deficient African American prostate tumors drives treatment resistance – Zoltan Szallasi (DF/HCC - BCH) and Shailja Pathania (UMass Boston).

概括 为医疗服务不足和代表性不足的人群提供服务的机构往往存在严重差距 学生（ISUPS）在获得基因组技术和与所需相关的高成本之间 仪器、技术熟练程度和分析专业知识弥补了这一差距。 通过以较低的费用提供专家和负担得起的高通量基因组学技术 对于所有合作伙伴研究人员而言，GC 通过提供创新方法来使整个合作伙伴关系受益。 探索早期的项目想法，并与合作伙伴研究人员及其受训人员合作，以促进使用 基因组学技术来建立可持续的癌症生物学和癌症差异研究。 这些目标，GC（通过个性化癌症治疗中心 (CPCT) 的支持）提供 一线基因组学相关技术，以及数据分析的生物信息学支持，以合作伙伴关系 GC 建议通过负担得起的报销模式来实现这些目标。 通过追求旨在建设生物医学和癌症研究能力的四个具体目标， 通过缩小基于尖端基因组学的支持的可用性的差距，在麻省大学波士顿分校进行培训； 希望追求早期项目想法的合作伙伴调查员，尤其是那些需要创新的项目想法 和/或技术上具有挑战性的基因组学方法；弥合学生和高水平人员之间的培训差距； 基于基因组学的技术，并提供在此核心中生成的数据的生物信息学分析。 应用程序中，GC 特别支持 FP2：针对男性前列腺癌中的雄激素受体信号传导 具有非洲血统的 – Steven Balk（DF/HCC - BIDMC）和 Changmeng Cai（麻省大学波士顿分校）和 PP2：高 BRCA2 缺陷的非洲裔美国前列腺肿瘤中 CHD1 缺失的频率导致治疗抵抗 – Zoltan Szallasi（DF/HCC - BCH）和 Shailja Pathania（麻省大学波士顿分校）。